Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52


A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B.

Blood. 2007 Mar 15;109(6):2276-84. Epub 2006 Nov 14.


Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A.

J Immunol. 2006 Apr 15;176(8):4757-65.


Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel J.

Blood. 2006 May 1;107(9):3575-83. Epub 2005 Nov 10.


Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.

Servida F, Soligo D, Delia D, Henderson C, Brancolini C, Lombardi L, Deliliers GL.

Leukemia. 2005 Dec;19(12):2324-31.


Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM.

Cancer Res. 2005 Sep 1;65(17):7896-901.


Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.

J Clin Oncol. 2005 Sep 1;23(25):6107-16.


Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS, Beaupre DM.

Clin Cancer Res. 2005 Aug 15;11(16):6057-64.


PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.

Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ.

Exp Hematol. 2005 Jul;33(7):784-95.


Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.

N Engl J Med. 2005 Jun 16;352(24):2487-98.


Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.

Boccadoro M, Morgan G, Cavenagh J.

Cancer Cell Int. 2005 Jun 1;5(1):18.


Proteasome inhibition as a novel therapeutic target in human cancer.

Rajkumar SV, Richardson PG, Hideshima T, Anderson KC.

J Clin Oncol. 2005 Jan 20;23(3):630-9. Review.


Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB.

Blood. 2005 Apr 15;105(8):3051-7. Epub 2005 Jan 4.


Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM.

Cell Death Differ. 2004 Dec;11 Suppl 2:S193-206.


Cure of myeloma: hype or reality?

Fassas A, Shaughnessy J, Barlogie B.

Bone Marrow Transplant. 2005 Feb;35(3):215-24. Review.


A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC.

Br J Haematol. 2004 Oct;127(2):165-72.


Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.

J Clin Oncol. 2004 Jun 1;22(11):2108-21.


Supplemental Content

Support Center